Preclinical evidence supporting the role of Alogabat, a GABA<sub>A</sub>-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders

Maria Clemencia Hernandez

[SC6-6] Preclinical evidence supporting the role of Alogabat, a GABA_A-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders

*Maria Clemencia Hernandez¹, Giuseppe Cecere¹, Theresa M Ballard¹, Michael Honer¹, Joerg F Hipp¹, Frederick Knoflach¹, Andres Olivares¹, Thomas Mueggler¹, Andreas Bruns¹, Pilar Graces¹, Basil Kuennecke¹, Barbara Biemans¹, Henner Knust¹, Eoin O'Connor¹, Michael Saxe¹, Lorraine Murtagh¹ (1. Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.)

Keywords:GABA-A α5 receptor, Alogabat, Neurodevelopmental disorders, Autism, Angelman syndrome

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Presentation information

Short Communications 6
Anxiety Disorders and Autism - Preclinical

[SC6-6] Preclinical evidence supporting the role of Alogabat, a GABA_A-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders

Password

Presentation information

Short Communications 6Anxiety Disorders and Autism - Preclinical

[SC6-6] Preclinical evidence supporting the role of Alogabat, a GABAA-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders

Password

Short Communications 6
Anxiety Disorders and Autism - Preclinical

[SC6-6] Preclinical evidence supporting the role of Alogabat, a GABA_A-α5 positive allosteric modulator, as a novel therapeutic approach for neurodevelopmental disorders